Protagenic Therapeutics, Inc.\new annual free cash flow
2014
2015
2015
2022
2023
2026
Protagenic Therapeutics, Inc.\new reported −$2.8M in free cash flow for fiscal 2026.
View full Protagenic Therapeutics, Inc.\new company overview| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2026 | 2026-03-31 | −$2.8M | — | — | — |
| 2023 | 2023-12-31 | −$3.9M | −$1.9M | — | — |
| 2022 | 2022-12-31 | −$2.0M | — | — | — |
| 2015 · Dec 31 | 2015-12-31 | −$383,132 | — | — | — |
| 2015 · Jun 30 | 2015-06-30 | −$379,000 | $412,000 | — | — |
| 2014 | 2014-06-30 | −$791,000 | — | — | — |
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | −$510,684 | — | — | — |
| Q4 2015 | 2015-06-30 | −$58,485 | $28,515 | — | — |
| Q3 2015 | 2015-03-31 | −$10,001 | $105,999 | — | — |
| Q2 2015 | 2014-12-31 | −$111,000 | $40,000 | — | — |
| Q1 2015 | 2014-09-30 | −$80,000 | $357,000 | — | — |
| Q4 2014 | 2014-06-30 | −$87,000 | — | — | — |
| Q3 2014 | 2014-03-31 | −$116,000 | — | — | — |
| Q2 2014 | 2013-12-31 | −$151,000 | — | — | — |
| Q1 2014 | 2013-09-30 | −$437,000 | — | — | — |
| Q3 2011 · Sep 30 | 2011-09-30 | −$294,000 | $3.1M | — | −2.39% |
| Q3 2011 · Sep 30 | 2010-09-30 | −$3.4M | — | — | −36.80% |
Protagenic Therapeutics, Inc.\new's latest reported quarter, Q4 2024, generated −$510,684 in free cash flow.
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Protagenic Therapeutics, Inc.\new source filings ↗